Genprex initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen initiated coverage of Genprex with a Buy rating and $10 price target. Genprex is a clinical-stage gene therapy company primarily focused on the development of therapeutic candidates for the treatment of non-small cell lung cancer and small cell lung cancer, the analyst tells investors in a research note. The analyst says incorporating an immunogene therapy with existing drugs could prolong lung cancer survival.